NCT01948817View on ClinicalTrials.gov

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
Interventions
DRUG

Deferasirox

Deferasirox 20mg/kg taken BID

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY